Innovative Therapeutics Neuron23 is a pioneering clinical-stage biotech focusing on precision medicines for neurological and immunological diseases, creating opportunities for partnerships in drug development, clinical trials, and specialized diagnostics.

Strong Financial Backing With recent Series D funding of $96.5M and a revenue range of $10M to $25M, Neuron23 demonstrates solid financial stability, facilitating potential collaborations or investment opportunities in research and commercialization.

Strategic Collaborations Partnerships with QIAGEN and Sano Genetics highlight a focus on diagnostic tools and patient recruitment, opening avenues for sales of companion diagnostics, testing platforms, and data analytics services.

Pipeline Expansion The launch of NEULARK and ongoing development of LRRK2-targeted therapies present opportunities to introduce complementary products, biomarkers, and disease-specific diagnostic solutions to enhance therapeutic efficacy.

Expert Team & Leadership With a dedicated team of 51-200 employees and key leadership appointments like the Chief Business Officer, Neuron23 is positioned for rapid growth, making it a compelling target for strategic partners interested in expanding innovation in neuroscience and immunology.